Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab.

Front Med (Lausanne) · 2020 · PMC7657267 · PMID 33195351

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Initial Inhibitor Level Although the initial inhibitor level showed a trend toward an increased risk of clinical relapse per unit increase the results did not meet statistical significance in the univariate analysis (HR: 1.16, 95% CI: 0.95, 1.44), p = 0.17.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.